Table 1

Baseline characteristics of randomly assigned patients

CharacteristicOverall
(n=171)
Arm A
PDS
(n=84)
Arm B
NACT
(n=87)
N (%)N (%)N (%)
Age (years), mean (SD)56.1 (10.4)54.8 (9.7)56.2 (10.7)
ECOG performance status
 079 (46.2)40 (47.6)39 (44.8)
 176 (44.4)35 (41.7)41 (47.1)
 216 (9.4)9 (10.7)7 (8)
CA125 serum level IU/ml, mean (SD) at diagnosis *2368.4 (3199.3)2653.5 (3944.2)2099.8 (2278.6)
Histotype
 High grade serous carcinoma167 (97.7)81 (96.4)86 (98.9)
 Low grade serous carcinoma2 (1.2)1 (1.2)1 (1.1)
 Clear cell carcinoma1 (0.6)1 (1.2)0 (0)
 Carcinosarcoma1 (0.6)1 (1.2)0 (0)
Grading
 G12 (1.2)1 (1.2)1 (1.1)
 G24 (2.4)2 (2.4)2 (2.3)
 G3164 (96.5)80 (96.4)84 (96.6)
 na110
FIGO surgical stage (2014)
 IIIC150 (87.7)71 (84.5)79 (90.8)
 IV21 (12.3)13 (15.5)8 (9.2)
 IVA12 (7)6 (7.1)6 (6.9)
 IVB9 (5.3)7 (8.3)2 (2.3)
Mean PI score at diagnosis (SD)9.3 (1.4)9.1 (1.4)9.4 (1.3)
  • *Information available for 169 patients: 82 in arm A, 87 in arm B.

  • ECOG, Eastern Cooperative Oncology Group; FIGO, International Federation of Gynecology and Obstetrics; NACT, neoadjuvant chemotherapy; PDS, primary debulking surgery; PI, predictive index.